SCHEMBL13850786

SCHEMBL13850786

COC(=O)c1cc(CO)c2cc(Cc3ccc(F)cc3)cnc2c1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PLA2G2A P14555 3/20 0.39
NR1H2 P55055 2/20 0.39
TDP1 Q9NUW8 2/20 0.38
TP53 P04637 1/20 0.38
PLA2G1B P04054 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
NR1H3 Q13133 1/20 0.37
SENP5 Q96HI0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850787 0.93 MAPT (0.42) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850788 0.92 MAPT (0.41) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850849 0.89 MAPT (0.42) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850761 0.89 MAPT (0.43) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850757 0.88 MAPT (0.43) MAPTHPGDALDH1A1TSHRHSD17B10
SCHEMBL13850852 0.88 MAPT (0.41) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850867 0.88 MAPT (0.42) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850850 0.88 MAPT (0.42) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL3872057 0.88 MAPT (0.42) MAPTLMNAHPGDL3MBTL1FFAR4
SCHEMBL13850816 0.87 MAPT (0.42) MAPTLMNAHPGDL3MBTL1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase MURAI HITOSHI 2009-05-07 US disclosed
US-7358249-B2 Heterocyclic compounds having inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118233-A1 Heterocyclic compounds having inhibitory activity against HIV integrase CYP3A7, CDK7, CYP2A7 MAPT 4308/4885LMNA 1842/4885HPGD 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.